Table 2.
Open in new tab

TNFi initiated in the PW and HW groups.

TNFi, n (%)PW
(n = 111)		HW
(n = 51)
Certolizumab pegol27 (24.3)11 (21.6)
Etanercept13 (11.7)9 (17.6)
Adalimumab37 (33.3)10 (19.6)
Infliximab10 (9.0)7 (13.7)
Golimumab24 (21.6)14 (27.5)
TNFi, n (%)PW
(n = 111)		HW
(n = 51)
Certolizumab pegol27 (24.3)11 (21.6)
Etanercept13 (11.7)9 (17.6)
Adalimumab37 (33.3)10 (19.6)
Infliximab10 (9.0)7 (13.7)
Golimumab24 (21.6)14 (27.5)

n: number of patients.

Table 2.
Open in new tab

TNFi initiated in the PW and HW groups.

TNFi, n (%)PW
(n = 111)		HW
(n = 51)
Certolizumab pegol27 (24.3)11 (21.6)
Etanercept13 (11.7)9 (17.6)
Adalimumab37 (33.3)10 (19.6)
Infliximab10 (9.0)7 (13.7)
Golimumab24 (21.6)14 (27.5)
TNFi, n (%)PW
(n = 111)		HW
(n = 51)
Certolizumab pegol27 (24.3)11 (21.6)
Etanercept13 (11.7)9 (17.6)
Adalimumab37 (33.3)10 (19.6)
Infliximab10 (9.0)7 (13.7)
Golimumab24 (21.6)14 (27.5)

n: number of patients.

Close
This Feature Is Available To Subscribers Only

Sign In or Create an Account

Close

This PDF is available to Subscribers Only

View Article Abstract & Purchase Options

For full access to this pdf, sign in to an existing account, or purchase an annual subscription.

Close